(Alliance News) - Tiziana Life Sciences PLC on Monday said the US Food & Drug Adminsitration has allowed the company to begin a phase 1 clinical trial of its novel Foralumab formulation in in Read More
(Alliance News) - Tiziana Life Sciences PLC on Tuesday said data from its phase 1 trial of Foralumab showed the drug "was well-tolerated at all doses" and produced a positive biomarker a Read More
(Alliance News) - Tiziana Life Sciences PLC on Wednesday announced positive data from its study of Milciclib in patients with advanced liver cancer.Shares in Tiziana were up 19% at 57.00 in Read More
(Alliance News) - Tiziana Life Sciences PLC on Monday said there were no drug related deaths in its phase 2a trial of Milciclib in advanced liver cancer and the drug was well tolerated with some 6 Read More
(Alliance News) - The following stocks are the leading risers and fallers within the main London indices on Monday.----------FTSE 100 - WINNERS----------DS Smith, Read More
(Alliance News) - Tiziana Life Sciences PLC on Monday noted a study in which a drug similar to Foralumab was shown to delay the onset of type-1 diabetes.Shares in the biotechnology company Read More
LONDON (Alliance News) - Tiziana Life Sciences PLC on Wednesday reported encouraging interim data from its trial of milciclib in patients with advanced liver cancer.Shares in Tiziana were - Read More
LONDON (Alliance News) - Tiziana Life Sciences PLC on Thursday reported a slight reduction in its annual loss as costs were reduced.For 2018, the clinical stage biotechnology company posted Read More
